About Centre

Participating entities

Almazov National Medical Research Centre

Federal State Budgetary Scientific Institution "Institute of Experimental Medicine"

The priority area for the research and development in the National science and technology of the Russian Federation: personalized medicine, high-tech healthcare and health preserving technologies

Major research areas of the WCRC

  • Population genetics and polygenic non-communicable diseases
  • Unknown, rare and genetically determined diseases
  • Oncology
  • Infectious diseases, microbial and antimicrobial therapy

Expected results of the implementation and development of the Centre

  • The Centre will conduct the first-ever large-scale genome-wide studies, identify the main spectrum of frequencies for genetic variants in the Russian population and construct genetic risk scores for the development and progression of major diseases that contribute to the structure of mortality in the Russian population (arterial hypertension, coronary artery disease, heart failure, diabetes mellitus, atrial fibrillation).
  • The Centre will identify at least twenty new mutations which are responsible for the development of genetically determined diseases and molecular targets for their treatment; will create at least 3 animal model lines and at least thirty model lines of induced pluripotent cells for biological modelling of diseases, at least one gene therapy drug that is unique in the world, for the management of congenital genetic disorders.
  • The Centre will develop at least three personalized drugs for cancer treatment based on genetically modified cells and use newly developed theranostic approaches for the diagnosis and treatment of neoplasms, including four new radiopharmaceuticals.
  • The Centre will create at least two new vaccines that have no counterparts in the world, for the treatment of chronic obstructive pulmonary diseases and infections caused by SARS-CoV-2; it will develop at least three personalized autoprobiotic drugs for the treatment of microbiota disorders in autoinflammatory diseases, metabolic disorders and cancer.